Latest posts from
What is New in Respiratory Medicine
Facebook Group
-
Thursday 30 Jul 2020
COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality.
Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of...
-
Thursday 30 Jul 2020
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants.
Original Article from The New England Journal of Medicine — Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
-
Thursday 30 Jul 2020
Platelets are essential mediators of inflammation and thrombosis. Chronic obstructive pulmonary disease (COPD) is a heterogeneous multisystem disease, causing significant morbidity and mortality worldwide. Recent evidence suggests that the lung is an important organ for platelet biogenesis. Cigarett...
-
Thursday 30 Jul 2020
Continuing on the blog series, "Finding Sanjivani, Daily". Historical perspective of the 'Inhaler Medications' is narrated briefly in 'Part-2'.
Quoting from the blog: "When we look back into the history of respiratory diseases other than tuberculosis - the decade of 1950 holds the greatest significance..... The understanding of airway diseases, its measurement of impact & the treatment - all got revolutionized in this decade."
Please click on the link below to read full blog:
https://m.zydushospitals.com/#!/blog_finding_sanjivani_daily_part_2.html
#AsthmaSpecialist
#BreathingProblem
#FindingSanjivaniDaily
#JaykumarMehtaInreventionalPulmonologist
-
Thursday 30 Jul 2020
Severe Covid-19 with cardiogenic shock due to cardiomyopathy An interesting case i today’s NEJM
Case Records of the Massachusetts General Hospital from The New England Journal of Medicine — Case 24-2020: A 44-Year-Old Woman with Chest Pain, Dyspnea, and Shock
-
Thursday 30 Jul 2020
A case of SARS-CoV-2 Pneumonia
Great discussion around ground glass opacities and imaging
Case Records of the Massachusetts General Hospital from The New England Journal of Medicine — Case 25-2020: A 47-Year-Old Woman with a Lung Mass
-
Wednesday 29 Jul 2020
Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19
Comment: interesting study, yet with a controversial outcome - high CRP may be indicative of bacterial infection in such patients. Clinical judgement is needed for such a decision.
This study was designed to determine whether systemic glucocorticoid treatment in COVID-19 patients is associated with reduced mortality or mechanical ventilation.
This observational study included 1,806 hospitalized COVID-19 patients; 140 were treated with glucocorticoids within 48 hours of admission.
Early use of glucocorticoids was not associated with mortality or mechanical ventilation.
Glucocorticoid treatment of patients with initial C-reactive protein (CRP) ≥20 mg/dL was associated with significantly reduced risk of mortality or mechanical ventilation (odds ratio, 0.23; 95% CI, 0.08-0.70)
Glucocorticoid treatment of patients with CRP <10 mg/dL was associated with significantly increased risk of mortality or mechanical ventilation (OR, 2.64; 95% CI, 1.39-5.03).
Whether glucocorticoid treatment is associated with changes in mortality or mechanical ventilation in patients with high or low CRP needs study in prospective, randomized clinical trials.
1Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York; 2Division of Rheumatology, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York; 3Division of Hospital M...
-
Wednesday 29 Jul 2020
Join us in the WiNRespMed Academy!
This is going to be the virtual interface for our What is New in Respiratory Medicine congress on September 18-20.
More to come soon!!!
See also the (almost) final program here:
; Faculty / Presenter(s) . Sep 18 2020; 304570;
-
Wednesday 29 Jul 2020
Αγαπητοί Συνάδελφοι,
Η Ένωση Πνευμονολόγων Ελλάδας βρίσκεται στην ευχάριστη θέση να σας ανακοινώσει ότι διαθέτει προς τους ενδιαφερόμενους Ιατρούς Πνευμονολόγους-Φυματιολόγους καθώς επίσης και προς ειδικευόμενους συναδέλφους οι οποίοι τυχόν ενδιαφέρονται, εκατό (100) εγγραφές ηλεκτρονικής διαδικτυακής παρακολούθησης του Συνεδρίου “What is New in Respiratory Medicine” που συνδιοργανώνει μαζί με την Πνευμονολογική Κλινική του Πανεπιστημίου Ιωαννίνων και το οποίο θα πραγματοποιηθεί στα Ιωάννινα 18-20 Σεπτεμβρίου 2020, στο ξενοδοχείο Du Lac.
Οι ενδιαφερόμενοι παρακαλούνται όπως αποστείλουν αίτημα εγγραφής στο email: info@epnel.gr, με καταληκτική ημερομηνία 31 Αυγούστου 2020.
ΠΡΟΣΟΧΗ: οι εγγραφές αφορούν μόνο διαδικτυακή παρακολούθηση - οι συνάδελφοι που θα παρακολουθήσουν το συνέδριο onsite θα έχουν δυνατότητα και διαδικτυακής παρακολούθησης.
Θα τηρηθεί σειρά προτεραιότητας.
Η παροχή των εγγραφών είναι μια ευγενική χορηγία της φαρμακευτικής εταιρείας GSK
ΤΟ ΠΑΝΕΛΛΗΝΙΟ ΣΥΝΕΔΡΙΟ ΤΗΣ ΕΝΩΣΗΣ ΠΝΕΥΜΟΝΟΛΟΓΩΝ ΕΛΛΑΔΑΣ ΣΕ ΣΥΝΕΡΓΑΣΙΑ ΜΕ ΤΗΝ ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΠΝΕΥΜΟΝΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΤΟΥ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΙΩΑΝΝΙΝΩΝ, ΘΑ ΠΡΑΓΜΑΤΟΠ....
-
Tuesday 28 Jul 2020
One of the many still unanswered questions regarding COVID-19 is the duration of protective immunity following infection. A recent report from China
-
Tuesday 28 Jul 2020
Dexamethasone and other steroids helped some hospitalized with COVID-19 but were potentially harmful when inflammation was low; a C-reactive protein test may identify those most likely to benefit.
-
Tuesday 28 Jul 2020
In mild to moderate sleep apnea, one night of portable sleep testing leads to substantial night-to-night AHI variability, which can cause a misclassification of disease severity: https://hubs.ly/H0s-x4M0
Read the accompanying editorial in journal CHEST®: https://hubs.ly/H0s-yr70
-
Tuesday 28 Jul 2020
Should you be wearing a face mask? Here's how they can make a difference in fighting coronavirus:
-
Tuesday 28 Jul 2020
It’s true the evidence for masks was weak before. That’s changed.
-
Tuesday 28 Jul 2020
This network meta-analysis of randomized trials estimates association of use of noninvasive ventilation (high-flow nasal oxygen; face mask or helmet noninvasive ventilation) vs standard oxygen therapy with mortality and endotracheal intubation among adults with acute hypoxemic respiratory failure.
-
Tuesday 28 Jul 2020
According to new research, the use of hydroxychloroquine among outpatients in clinical trials, without high-risk factors for cardiac arrhythmia, is safe.
-
Tuesday 28 Jul 2020
According to new research, the use of hydroxychloroquine among outpatients in clinical trials, without high-risk factors for cardiac arrhythmia, is safe.
-
Monday 27 Jul 2020
By Kelly YoungEdited by Susan Sadoughi, MD, and André Sofair, MD, MPHCheck out some of the recent developments on COVID-19: Prolonged, mild illness:
-
Monday 27 Jul 2020
An international team created a mobile device app that allows users to report repeatedly on symptoms thought to be relevant for COVID-19 and to
-
Sunday 26 Jul 2020
Presence of Genetic Variants Among Young Men With Severe COVID-19
In a case series that included 4 young male patients with severe COVID-19 from 2 families, rare loss-of-function variants of the X-chromosomal TLR7 were identified, with immunological defects in type I and II interferon production.
A possible explanation for severe Covid-19 disease in patients with a genetic defect in interferon production.
This case series describes rare putative X-chromosomal loss-of-function variants associated with impaired peripheral mononuclear blood cell interferon signaling in 4 young male patients hospitalized with severe coronavirus disease 2019 (COVID-19) in the Netherlands.
